Literature DB >> 492193

The effects of beta-radiation on sister-chromatid exchanges in cultured human lymphocytes.

P E Crossen, W F Morgan.   

Abstract

The incidence of Sister-Chromatid Exchanges (SCEs) due to beta-radiation was investigated in cultured human lymphocytes using the BrdU/Giemsa technique. Cultures treated continuously with 0.001 and 0.01 microCi of [3H]uridine showed no increase in either chromosome abnormalities or SCEs. Continuous treatment with 0.1 microCi resulted in a significant increase in chromosome aberrations but no increase in SCEs, while treatment with 0.2 microCi gave both an increase in chromosome aberrations and SCEs. Cultures given a 4-h pulse with 1.0 microCi showed a significant increase in both SCEs and chromosome aberrations. The results indicate that low levels of beta-radiation do not cause an increase in SCEs in human lymphocytes, and, that a number, if not all the exchanges observed at low levels of beta-radiation with autoradiography, may be spontaneous events.

Entities:  

Mesh:

Year:  1979        PMID: 492193     DOI: 10.1016/0027-5107(79)90225-2

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  4 in total

1.  A family study of spontaneous sister chromatid exchange frequency.

Authors:  M M Cohen; A O Martin; C Ober; S J Simpson
Journal:  Am J Hum Genet       Date:  1982-03       Impact factor: 11.025

Review 2.  Sister chromatid exchange (SCE) and structural chromosome aberration in mutagenicity testing.

Authors:  E Gebhart
Journal:  Hum Genet       Date:  1981       Impact factor: 4.132

3.  Can 3H-uridine-induced sister chromatid exchange be used as a measure of transcriptional activity of chromosomes?

Authors:  A L Lavelle; J A Graves
Journal:  Chromosoma       Date:  1982       Impact factor: 4.316

4.  Variation in the sensitivity of human lymphocytes to DNA-damaging agents measured by sister chromatid exchange frequency.

Authors:  P E Crossen
Journal:  Hum Genet       Date:  1982       Impact factor: 4.132

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.